Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases

• Published in: Neurological research (New York) Vol. 25; no. 4; p. 335
• Main Authors: Gerlach, Rüdiger, Scheuer, Timm, Böhm, Martina, Beck, Jürgen, Woszczyk, Alina, Raabe, Andreas, Scharrer, Inge, Seifert, Volker
• Format: Journal Article
• Language: English
• Published: England 01.06.2003
• Subjects: Adult; Aged; Astrocytoma - blood; Astrocytoma - secondary; Brain Neoplasms - blood; Brain Neoplasms - pathology; Female; Glioblastoma - blood; Glioblastoma - secondary; Hemangioblastoma - blood; Hemangioblastoma - secondary; Humans; Lipoproteins - blood; Male; Meningeal Neoplasms - blood; Meningeal Neoplasms - secondary; Meningioma - blood; Meningioma - secondary; Middle Aged; Neurilemmoma - blood; Neurilemmoma - secondary; Oligodendroglioma - blood; Oligodendroglioma - secondary; Pituitary Neoplasms - blood; Pituitary Neoplasms - secondary
• DOI: 10.1179/016164103101201652
• ISSN: 0161-6412

Tissue Factor Pathway Inhibitor (TFPI) prevents further participation of Tissue Factor (TF) in the coagulation process by forming a stable quaternary complex of TF-FVIIa-FXa-TFPI. Recently, plasma TFPI level were found to be elevated in patients with malignant disease outside the brain. Therefore the aim of this study was to investigate the TFPI plasma level in patients with primary brain tumors and intracerebral metastases. From May 2000 to December 2001 the total tissue factor pathway inhibitor antigen (TFPI) was preoperatively determined in blood samples of 225 patients with primary or metastatic brain tumors. Tumor histology classified as benign (WHO grade I and II) and malignant (WHO grade III and IV, intracerebral metastases) was correlated to plasma TFPI-levels. Plasma TFPI was significantly higher in patients with malignant tumors including intracerebral metastasis compared to benign tumors (80.1 +/- 34.31 versus 64.3 +/- 25.8 ng ml-1 [p < 0.01; t-test]). To exclude the influence of primary systemic neoplasms with secondary brain metastasis on plasma TFPI-level a subgroup of patients with primary brain tumors (meningioma, astrocytoma, oligodendroglioma and glioblastoma) was separated. In this group TFPI-level was also significantly elevated in patients with malignant (n = 66) (78.6 +/- 29.9) compared to benign brain tumors (n = 127) (64.3 +/- 25.8 ng ml-1 [p < 0.01; t-test]). To the authors' knowledge this is the first study describing the correlation of increased plasma TFPI and malignancy in patient with brain tumors. Further studies are needed to clarify the pathogenic mechanism and the clinical relevance of this phenomenon.